Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CARAMEL IST is an investigator-sponsored clinical trial program developed by Century Therapeutics in collaboration with Friedrich-Alexander University Erlangen-Nürnberg. The program utilizes allogeneic iT cell therapy derived from induced pluripotent stem cells (iPSCs) engineered with Century's proprietary Allo-Evasion™ 5.0 technology. This platform is designed to create off-the-shelf cell therapies that can evade the host immune system, potentially allowing for repeat dosing and broader patient access. The CARAMEL IST is being evaluated for the treatment of B-cell-mediated autoimmune diseases, solid tumors, and other indications, representing a versatile approach to cell-based immunotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CARAMEL IST.